Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Spherix Global Insights notes that differentiation among the IL-23 therapies “will be essential” as Tremfya and Omvoh look to battle class front-runner Skyrizi. (AbbVie) The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly growing into the established UC market as
Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for Fabhalta or Empaveli, if approved. EXTON, PA, November 15, 2024 — Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G
Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation. Exton, PA., November 15, 2024 – In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson &
The introduction of biologic therapies for hidradenitis suppurativa (HS) has “revolutionized” treatment for the rare inflammatory skin condition, though there’s still plenty of progress to be made, according to Spherix Global Insights. A new white paper from the market research firm charts the impact of the introduction of biologics as a treatment
Spherix Global Insights’ White Paper Highlights MarketExpansion and Strategies for Opportunities in HS. Exton, PA, November 7, 2024 — Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa, underscoring how early intervention with advanced therapies can significantly enhance
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. According to Spherix analysts, Rezdiffra “has seen rapid uptake,” with more than 60% of gastroenterologists and hepatologists surveyed in October
Systemic sclerosis is the most challenging diagnosis to make among rheumatic and autoimmune conditions, according to 91% of respondents in a market analysis from Spherix Global Insights. “I agree with the survey responses in that the rheumatologists highlighted systemic sclerosis as the most challenging diagnosis and the most challenging disease to manage
US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights. EXTON, PA., November 1, 2024 — Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney diseases with critical unmet therapeutic needs,
More than half of dermatomyositis patients are not optimally managed, according to a survey of 102 U.S. rheumatologists and dermatologists by Spherix Global Insights. Currently, the standard of care predominantly involves corticosteroids, topical therapies, traditional disease-modifying anti-rheumatic drugs (tDMARDs), and, in more severe or refractory cases, intravenous immunoglobulin (IVIg) or
Although CSL Behring’s Hizentra (IgPro20) is touted as akey pipeline agent to watch, rheumatologists currently prefer AstraZeneca’sSaphnelo (anifrolumab), while dermatologists favor Priovant Therapeutics’brepocitinib. Exton, PA, October 18, 2024 – Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care
With the potential rise of new oral agents, dermatologists are increasingly optimistic about safer, more convenienttreatment options for psoriasis, according to Spherix Global Insights. Exton, PA, October 16, 2024 – Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing
Incorporation of gene therapies, such as Beqvez (Pfizer),Hemgenix (CSL Behring) and Roctavian (BioMarin), and potential future approvalsof fitusiran (Sanofi) and Mim8/denecimig (Novo Nordisk) will further drive theincreasingly dynamic hemophilia markets. Exton, PA – October 14, 2024 – Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide.
Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in the lupus nephritis treatment landscape, pending approval. EXTON, PA., October 10, 2024 – While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for
AbbVie now faces a more seasoned rival than Eli Lilly. (AbbVie) Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, capturing more than double the market share of its rival two months after launch. But AbbVie now faces another challenger, with Spherix predicting a similarly
Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s. EXTON, PA., October 02, 2024 — Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient’s overall functioning. Common symptoms include significant dryness, particularly in the eyes
With Tremfya also securing approval in UC earlier this month, competition promises to be fierce among the IL-23s, according to Spherix Global Insights. Exton, PA., October 1, 2024 – The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
